There is evidence that higher doses of fulvestrant (Faslodex) may have greater activity than the approved dose of 250 mg/mo. The FIRST trial (Fulvestrant First-Line Study) compared 500 mg vs anastrozole(Drug information on anastrozole) 1 mg/d in the first-line advanced disease setting, finding that a dose of 500 mg/mo achieved response rates and clinical benefit rates similar to those obtained with anastrozole 1 mg/d but gave a significantly longer time to progression (abstract 6126).
The multicenter open-label study randomized 205 postmenopausal advanced breast cancer patients to fulvestrant HD (two 250-mg injections) on or about days 0, 14, and 28, and monthly thereafter, or to 1 mg/d of oral anastrozole. For 75% of patients, this was the first line of treatment for advanced disease.
The investigator-determined response rates were 36% and 35.5%, respectively, in the fulvestrant and anastrozole arms. With fulvestrant HD, the clinical benefit rate (response plus stable disease for = 24 wk) was numerically higher at 72.5% vs 67% with anastrozole. Time to progression (TTP), however, was signifi cantly longer for fulvestrant HD, with a hazard ratio of 0.63 (P < .05). Median TTP had not been reached as compared with a median TTP of 12.5 months for anastrozole.
“At the data cutoff , 29.4% of patients treated with high-dose fulvestrant had progressed compared with 41.7% of those in the anastrozole group,” reported Matthew J. Ellis, MD, PhD.
Median duration of response and duration of clinical benefit both favored fulvestrant HD.
The fulvestrant HD regimen was well tolerated, with an adverse event profile comparable with that of anastrozole and consistent with that previously reported for the standard dose. The incidence of injection site pain with fulvestrant HD (5.9%) was similar to that seen with fulvestrant 250 mg (4.6%), despite there being twice as many injections per month in the HD regimen.
The ongoing phase III CONFIRM trial (Comparison of Fulvestrant in Recurrent or Metastatic Breast Cancer) is evaluating fulvestrant 500 mg vs 250 mg per month, which should help clarify the role of the higher dose, Dr. Ellis added.
|
Oncology NEWS International. Vol. 18 No. 2 Supplement
Highlights from the
2008 San Antonio Breast Cancer Symposium
High-Dose Fulvestrant at Least as Good as Anastrozole in First-Line MBC
By Guest Editor Aman U. Buzdar, MD
The University of Texas MD Anderson Cancer Center | February 1, 2009
|
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office. Growing HIPAA Threat – Ignore Windows XP at Your Own Peril Marion K. Jenkins, May 21, 2013 Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003. Finding Physician Work-Life Balance in the Small Moments Jennifer Frank, MD, May 21, 2013 At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs. Three Areas to Reduce Costs at Your Medical Practice Greg Mertz, May 19, 2013 By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation. Dos and Don’ts for Starting a Physician Blog Michael Woo-Ming, MD, May 18, 2013 Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
CancerNetwork on Facebook
|
CancerNetwork |
ConsultantLive |
Diagnostic Imaging |
Musculoskeletal Network |
OBGYN.net |
PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy